Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ONFI vs LEVOPROME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.
Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.
Treatment of seizures associated with Lennox-Gastaut syndrome,Adjunctive therapy for other seizure types
Psychotic disorders,Schizophrenia,Acute mania,Nausea and vomiting,Intractable hiccups
Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.
25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.
The terminal elimination half-life of clobazam is 36–42 hours. The active metabolite N-desmethylclobazam has a half-life of 71–82 hours. The long half-life permits once-daily dosing but also leads to slow accumulation; steady-state is achieved after 2–3 weeks.
Terminal elimination half-life is approximately 24 hours (range 12–36 hours). Accumulation occurs with repeated dosing, requiring dose adjustment in hepatic impairment.
Hepatic via CYP3A4 and CYP2C19; primary metabolite N-desmethylclobazam is active.
Hepatic via CYP2D6, CYP3A4; active metabolites include methotrimeprazine sulfoxide, N-desmethylmethotrimeprazine.
Clobazam (ONFI) undergoes extensive hepatic metabolism. Approximately 82% of the dose is eliminated in urine (as unchanged drug and metabolites) and about 11% in feces. Unchanged clobazam accounts for <1% of urinary excretion. The major metabolite, N-desmethylclobazam, is excreted primarily renally.
Primarily renal (approx. 70% as conjugated metabolites, <1% unchanged), with biliary/fecal excretion (approx. 20%).
Clobazam is approximately 80–90% bound to plasma proteins, primarily albumin.
>99% bound, primarily to albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution is approximately 100 L (range 77–120 L), or roughly 1.4 L/kg. This large Vd indicates extensive tissue distribution and accumulation in fatty tissues.
Approximately 7 L/kg (range 5–10 L/kg), indicating extensive tissue distribution.
Oral bioavailability is nearly complete (>90%). Clobazam is well absorbed after oral administration with only minor first-pass metabolism.
Oral: 40–50% (first-pass effect); Intramuscular: 70–80%.
No specific GFR-based dose adjustments; use with caution in severe impairment (Cr Cl < 30 m L/min) due to potential for increased sedation.
Cr Cl 10-50 m L/min: Administer 75% of usual dose; Cr Cl <10 m L/min: Administer 50% of usual dose.
Mild to moderate (Child-Pugh A/B): Initial 5 mg orally twice daily; may increase by 5 mg/day after 1 week to maximum 20 mg/day. Severe (Child-Pugh C): Not recommended.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 25-50%; Child-Pugh Class C: Avoid use.
Clobazam (ONFI) for seizures: Age 2 to <6 years, body weight ≥12.5 kg: Initial 5 mg orally once daily; titrate to maintenance 5 mg twice daily. Age ≥6 years: Weight ≤30 kg: Initial 5 mg once daily; titrate to 5 mg twice daily (max 20 mg/day). Weight >30 kg: same as adult dosing. Administer with food.
Children >12 years: 0.5-1 mg/kg intramuscularly every 6-8 hours; maximum 2 mg/kg/day. Not recommended for children under 12 years.
Elderly (≥65 years): Initial 5 mg orally twice daily; increase slowly to lowest effective maintenance due to increased sensitivity and risk of falls. Avoid doses above 20 mg/day unless clearly necessary.
Initial dose: 12.5 to 25 mg intramuscularly; titrate cautiously due to increased sensitivity and risk of orthostatic hypotension.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients for whom alternative treatment options are inadequate.
Increased mortality in elderly patients with dementia-related psychosis; risk of tardive dyskinesia; neuroleptic malignant syndrome (NMS).
Risk of respiratory depression, especially with opioids,Sedation and somnolence,Risk of abuse and dependence,Withdrawal seizures on abrupt discontinuation,Increased risk of suicidal thoughts or behavior
Neuroleptic malignant syndrome, tardive dyskinesia, hypotension, seizures, anticholinergic effects, QT prolongation, agranulocytosis, photosensitivity, elevation of prolactin levels.
Hypersensitivity to clobazam or any component of formulation,Severe hepatic impairment
Comatose states, CNS depression, bone marrow suppression, pheochromocytoma, hypersensitivity to phenothiazines, concurrent use with high-dose CNS depressants.
Avoid grapefruit and grapefruit juice as they may increase clobazam levels. No other significant food interactions are known. CNS depressant effects may be potentiated by alcohol.
Avoid grapefruit and grapefruit juice as they may increase serum levels of methotrimeprazine. Limit caffeine intake as it may exacerbate side effects like restlessness. No specific food restrictions otherwise.
Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia, poor feeding, respiratory depression, and hypothermia; consistent exposure may cause floppy infant syndrome. Late pregnancy exposure linked to neonatal benzodiazepine withdrawal syndrome.
First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations; risk of neonatal extrapyramidal symptoms and jaundice with third-trimester use.
Clobazam is excreted into breast milk; M/P ratio approximately 0.5-0.6. Accumulation possible in neonates; monitor for sedation, poor feeding, apnea. Avoid if infant has impaired hepatic function or low birth weight. American Academy of Pediatrics recommends caution; use lowest effective maternal dose.
Levofloxacin (levoprome) is excreted in human milk; M/P ratio approximately 0.8. Avoid breastfeeding during therapy due to potential adverse effects on infant cartilage development.
Increased clearance during pregnancy (CYP3A4 induction); plasma concentrations may decrease by 30-50% in third trimester. Dose adjustments often required: monitor therapeutic response and consider dose increase by 50-100% in late pregnancy; postpartum reduce to prepregnancy dose over 1-2 weeks to avoid toxicity.
No dosage adjustment required based on pregnancy-related pharmacokinetic changes; however, use only if clearly needed due to theoretical risks to fetus.
ONFI (clobazam) is a benzodiazepine indicated for seizures associated with Lennox-Gastaut syndrome. Titrate slowly to minimize sedation. Monitor for withdrawal symptoms upon discontinuation; taper over several weeks. Not recommended for use in patients with severe hepatic impairment (Child-Pugh C). For patients on other CNS depressants, consider dose reduction. Clobazam's active metabolite, N-desmethylclobazam, has a long half-life (36-46 hours) and can accumulate, especially in poor CYP2C19 metabolizers. In such patients, consider lower doses and monitor for excessive sedation.
Levoprome (methotrimeprazine) is a phenothiazine neuroleptic with potent analgesic properties. It may cause significant hypotension, especially in elderly or hypovolemic patients; use with caution and monitor blood pressure. Extrapyramidal symptoms are less common than with typical antipsychotics but may occur. Avoid subcutaneous extravasation due to tissue irritation.
Take ONFI exactly as prescribed; do not stop suddenly as withdrawal seizures may occur.,Avoid alcohol and other sedatives while taking this medication due to increased risk of drowsiness and respiratory depression.,Report any unusual mood changes, depression, or suicidal thoughts to your healthcare provider.,Do not drive or operate heavy machinery until you know how ONFI affects you, as it can cause dizziness and drowsiness.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using ONFI.,Store at room temperature, away from moisture and heat.
This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Avoid alcohol and other central nervous system depressants.,Rise slowly from sitting or lying positions to prevent fainting.,Report any unusual muscle movements or stiffness to your healthcare provider.,Use sunscreen and protective clothing as this drug may increase sensitivity to sunlight.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ONFI vs LEVOPROME, answered by our medical review team.
ONFI is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases the frequency of chloride channel opening in response to GABA.. LEVOPROME is a Phenothiazine Antipsychotic that works by Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ONFI and LEVOPROME depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ONFI is: Initial: 10 mg orally twice daily; may increase by 10 mg/day after 1 week to maintenance of 20–40 mg/day in two divided doses. Maximum: 60 mg/day.. The standard adult dose of LEVOPROME is: 25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ONFI and LEVOPROME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ONFI is classified as Category C. Pregnancy Category C. First trimester: increased risk of major malformations including cleft lip/palate (OR 2.0-3.0); second/third trimester: risk of neonatal withdrawal, hypotonia. LEVOPROME is classified as Category C. First trimester: Limited data; animal studies show increased fetal resorption and skeletal anomalies at high doses. Second and third trimesters: No evidence of major malformations;. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.